Show simple item record

dc.contributor.authorShute, Travis
dc.contributor.authorAmiel, Eyal
dc.contributor.authorAlam, Noran
dc.contributor.authorYates, Jennifer L.
dc.contributor.authorMohrs, Katya
dc.contributor.authorDudley, Elizabeth
dc.contributor.authorSalas, Briana
dc.contributor.authorMesa, Chloe
dc.contributor.authorSerrata, Adriana
dc.contributor.authorAngel, Daniel
dc.contributor.authorVincent, Brandy K.
dc.contributor.authorWeyers, Amanda
dc.contributor.authorLanthier, Paula A.
dc.contributor.authorVomhof-Dekrey, Emilie
dc.contributor.authorFromme, Rachel
dc.contributor.authorLaughlin, Mitchell
dc.contributor.authorDurham, Olivia
dc.contributor.authorMiao, Jianjun
dc.contributor.authorShipp, Devon
dc.contributor.authorLinhardt, Robert J.
dc.contributor.authorNash, Kelly
dc.contributor.authorLeadbetter, Elizabeth A.
dc.date2021
dc.date.accessioned2022-06-27T15:36:08Z
dc.date.available2022-06-27T15:36:08Z
dc.date.issued2021-04-15
dc.identifier.citationGlycolipid-containing nanoparticle vaccine engages invariant NKT cells to enhance humoral protection against systemic bacterial infection but abrogates T-independent vaccine responses, T. Shute, E. Amiel, N. Alam, J. L. Yates, K. Mohrs, E. Dudley, B. Salas, C. Mesa, A. Serrata, D. Angel, B. K. Vincent, A. Weyers, P. A. Lanthier, E. Vomhof-Dekrey, R. Fromme, M. Laughlin, O. Durham, J. Miao, D. Shipp, R. J. Linhardt, K. Nash, E. A. Leadbetter, Journal of Immunology, 206, 1806–1816, 2021.
dc.identifier.issn15506606
dc.identifier.issn221767
dc.identifier.urihttps://doi.org/10.4049/jimmunol.2001283
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5449
dc.descriptionJournal of Immunology, 206, 1806–1816
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractCD4+ T cells enable the critical B cell humoral immune protection afforded by most effective vaccines. We and others have recently identified an alternative source of help for B cells in mice, invariant NK T (iNKT) cells. iNKT cells are innate glycolipid-specific T cells restricted to the nonpolymorphic Ag-presenting molecule CD1d. As such, iNKT cells respond to glycolipids equally well in all people, making them an appealing adjuvant for universal vaccines. We tested the potential for the iNKT glycolipid agonist, α-galactosylceramide (αGC), to serve as an adjuvant for a known human protective epitope by creating a nanoparticle that delivers αGC plus antigenic polysaccharides from Streptococcus pneumoniae αGC-embedded nanoparticles activate murine iNKT cells and B cells in vitro and in vivo, facilitate significant dose sparing, and avoid iNKT anergy. Nanoparticles containing αGC plus S. pneumoniae polysaccharides elicits robust IgM and IgG in vivo and protect mice against lethal systemic S. pneumoniae However, codelivery of αGC via nanoparticles actually eliminated Ab protection elicited by a T-independent S. pneumoniae vaccine. This is consistent with previous studies demonstrating iNKT cell help for B cells following acute activation, but negative regulation of B cells during chronic inflammation. αGC-containing nanoparticles represent a viable platform for broadly efficacious vaccines against deadly human pathogens, but their potential for eliminating B cells under certain conditions suggests further clarity on iNKT cell interactions with B cells is warranted.
dc.description.sponsorshipNational Institutes of Health
dc.languageen_US
dc.language.isoENG
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofJournal of Immunology
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleGlycolipid-containing nanoparticle vaccine engages invariant NKT cells to enhance humoral protection against systemic bacterial infection but abrogates T-independent vaccine responses
dc.typeArticle
dcterms.isPartOfJournal
dcterms.isVersionOfhttps://doi.org/10.4049/jimmunol.2001283
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
rpi.description.pages1806-1816
rpi.description.volume206


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record